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A b s t r a c t  
Sustained release (SR) matrix tablets of losartan potassium were prepared by wet granulation using 
xanthene as the polymer. The studies indicated that the drug release can be modulated by varying 
the concentration of the polymer and the fillers. The estimation of losartan potassium from human 
plasma method involves simple protein precipitation techniques using nifedipine as internal 
standard. Chromatographic separation was carried out on a reversed phase C18 column using 
mixture of 0.5% triethyl amine (pH 3.5) and acetonitrile (60:40, v/v) at a flow rate of 1.0 mL/min with 
UV detection at 225 nm. The method was validated and found to be linear in the range of 20-300 
ng/ml. An open, randomized, two-treatment, two period, single dose crossover, bioavailability study 
in 24 fasting, healthy, male, volunteers was conducted. Various pharmacokinetic parameters 
including AUC0ăt, AUC0ă¥, Cmax, Tmax, T1/2, and elimination rate constant (Kel) were determined from 
plasma concentration of both formulations. These results indicated that the analytical method was 
linear, precise and accurate. The sustained and efficient drug delivery system developed in the 
present study will maintain plasma losartan potassium levels better, which will overcome the 
drawbacks associated with the conventional therapy. 
Keywords: In vivo evaluation; Sustained release; Dissolution; pharmacokinetic studies. 
Introduction 
Losartan potassium (LP) is chemically 2-butyl-4-chloro-1-[p-(o-1H-
tetrazol-5ylphenyl)benzyl]imidazole-5-methanol monopotassium 
salt. LRT is the first of a unique class of oral antihypertensive 
agents referred to as angiotensin II receptor antagonists 1. It is an 
antihypertensive agent. Besides a couple of Analytical and 
bioanalytical methods 2-12 not much literature is reported for the 
determination of losartan potassium in biological samples. 
Therefore, the aim of the present investigation was to develop a 
new, sensitive (20 ng/ml) HPLC method for the estimation of 
losartan potassium in human plasma. The method was applied to 
a bioequivalence study of losartan potassium 5.0 mg tablets. The 
outcome of a study depends upon the reliability, reproducibility 
and sensitivity of the analytical methodology employed. Therefore, 
the bioanalytical method was validated in accordance with 
USFDA guidelines prior to the initiation of the study. 
Experimental 
Chemicals and reagents 
Working standard of losartan potassium with 99.96% purity was 
obtained from German Remedies Ltd., Mumbai, India. nifedipine 
(purity 99.56%) working standard was obtained from Cadila 
Health Care Ltd., Ahmedabad, India).  Acetonitrile (HPLC grade), 
obtained from Qualigens Fine Chemicals, Mumbai ortho 
phosphoric acid, methanol, and perchloric acid (all analytical 
grade reagent) were purchased from S.D. Fine Chem. Ltd., 
Mumbai. Losartan Potassium was a gift sample from Vasudha 
Pharma Chem Ltd (Hyderabad, India). HPMC (Methocel ă K100ă
CR, apparent viscosity, 2% in water at 20ĈC is 80,000-12000 cP), 
xanthen and starch 1500 were gift samples from Colorcon Asia 
Pvt Ltd (Goa, India). Polyvinyl pyrrolidine (PVP-K-30) was a gift 
sample from Anshul Agencies (Mumbai, India). Aerosil was 
purchased from Degussa India Pvt Ltd (Mumbai, India). In house 
mill Q water was used throughout the study. Fresh frozen human 
plasma used in the method development was obtained from the 
Vijay Hospital, Ooty, and was stored at î20 ◦C until required.  
Development of Losartan potassium Sustained 
Release (SR) tablets 
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Losartan potassium SR tablets were prepared by the wet 
granulation method. All the composition, with the exception of 
magnesium stearate and aerosil were thoroughly mixed in a 
tumbling mixer for 5 min and wetted in a mortar with isopropyl 
alcohol. The wet mass was sieved (16 mesh) and granules were 
dried at 60ĈC for 2 h. The dried granules were sieved (22 mesh) 
and these granules were lubricated with a mixture of magnesium 
stearate and aerosil (2:1). The losartan potassium tablets were 
prepared using an electrically operated punching machine. 
Compression was performed after granulation process with a 
single punch press applying a compression force of a 9 KN 
(preliminary work) or 12 KN (experimental design), equipped with 
a 6 mm flat-faced punch. For the preliminary work, batches of 100 
tablets were prepared. Each batch of experimental design 
consisted of 100 tablets (drug content in the tablet was 25 mg). 
Three batches were prepared for each formulation and the 
compositions of different batches of losartan potassium SR tablets 
are given in Table 1. The compressed tablets were evaluated for 
average weight & weight variation, thickness, diameter, drug 
content and content uniformity, hardness, friability, disintegration 
and In vitro drug release. 
Instrumentation and chromatography 
The HPLC system consisted of a HPLC 2010 A HT (Shimadzu 
Ltd., Japan), Auto injector port with 100øL loop (Rheodyne, USA) 
and UV detector (Shimadzu Ltd., Japan). The wavelength of the 
detector was set at 225 nm. Detector output was quantified on 
CLASS VP (Version 6.01) chromatography software. Separation 
was carried out on a Princeton SHER C18, 4.6øm ï 250 mm, 
Japan, using mixture of 0.5% triethyl amine (pH 3.5) and 
acetonitrile (60:40, v/v) as a mobile phase, at a flow rate of 1 
mL/min. Total analysis time was 10 min. All analysis was 
performed at room temperature 13-18.  
Preparation of calibration standard 
Stock solutions of losartan potassium and nifedipine (I.S) (1 
mg/mL) were in water and stored at 4◦C. The stock solution of 
losartan potassium was further diluted with water to 
give series of standard solutions. Calibration standard of losartan 
potassium (20,60,80,101,120,150,182 and 300, ng/ml) were 
prepared by spiking appropriate amount of the standard solution 
in blank plasma. 
Quality control standards 
Lowest quality control standards (LQC), median quality control 
standards (MQC) & highest quality control standards (HQC) were 
prepared by spiking drug free plasma with losartan potassium to 
give solutions containing 101, 150 and 182 ng/ml, respectively. 
They were stored at î20 ◦C till analysed. 
Sample preparation 
Calibration standards, validation QC samples and healthy 
volunteer plasma samples were prepared by adding 0.5 ml 
plasma to 2.0ml centrifuge tube and added 0.5 ml (10 øg/ml) of 
internal standard and 0.5 ml of precipitating agent (10% v/v 
perchloric acid) vortexed for 2 min. The resulting solution was 
centrifuged at 4000 rpm for 7 min. The supernatant layer was 
separated and estimated by HPLC. 
Validation 
Validation is a process which involves confirmation or 
establishment by laboratory studies that a method / procedure / 
system / analyst can give the required accuracy, precision, 
sensitivity, ruggedness, etc. In the most basic form, validation of 
an analytical procedure demonstrates that the procedure 
developed is suitable for its intended purpose.  Validation of the 
method was carried out after the development of the HPLC 
methods. Validation parameters tested were, Selectivity/ 
Specificity, Sensitivity, Linearity, Precision and Accuracy, Within-
batch precision and accuracy, Intra-day precision and accuracy, 
between batch / Inter-day precision and accuracy. Stabilities, 
Short Term Stock Dilution Stability, Long Term Stock Solution 
Stability, Freeze Thaw Stability, Bench Top (BT) Stability, Long-
Term (LT) Stability, Autosampler Stability, Recovery, 
Ruggedness, Robustness. 
Selectivity/ Specificity 
A method is said to be specific when it produces a response only 
for a single analyte.  Method selectivity is the ability of the method 
to produce a response for the analyte in the presence of other 
interferences. In order to prove that the method chosen was 
specific and selective the following two sets of samples were 
processed and injected into the HPLC using the extraction 
procedure. Blank samples from six different lots of biological 
matrix (plasma containing  K2 EDTA as anticoagulant). Samples 
from the same six lots of biological matrix mentioned in step 
spiked with the analyte at the lower limit of quantification (LLOQ) 
of the calibration curve and with the internal standard at the 
concentration level in the study. 
Sensitivity 
It is expressed as limit of quantitation. It is the lowest amount of 
analyte in a sample matrix that can be determined. The lower limit 
of quantification for losartan potassium was 20.0 ng/ml. 
Linearity 
Linearity and range of the methods were analyzed by preparing 
calibration curves using different concentrations of the standard 
solution containing the internal standard. The calibration curve 
was plotted using response factor and concentration of the 
standard solutions. Linearity was established using four 
calibration curves over the range of  20.0 to 300.0 ng/ml for 
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losartan potassium using the weighted least square regression 
analysis. 
A calibration curve consisted of Aqueous standard at middle 
concentration level to check retention time of analyte and internal 
standard.Blank sample (matrix sample processed without internal 
standard and analyte). Zero sample (matrix sample processed 
with internal standard but without analyte) Eight non-zero 
standards covering the expected range.  The lowest and highest 
standards were prepared in duplicates. 
Precision and Accuracy 
The precision and accuracy of the method was determined by 
analyzing two batches each consisting of one set of calibration 
curve with  six replicates of quality control samples at four 
concentration levels [Quality Control samples at the lower limit of 
quantification (QCLLQ), Low (QCL), Middle (QCM) and 
High(QCH)].   
Precision 
Precision is expressed as the percentage coefficient of variation 
(%CV) which is calculated. 
Intra-run Precision 
Intra-run precision was determined by calculating the percentage 
coefficient of variation (% CV) of the results obtained in the same 
run. 
Intra-day Precision 
Intra-day precision was determined by calculating the percentage 
coefficient of variation (% CV) of the results obtained in the same 
day. 
Inter-day Precision 
Inter-day precision was determined by calculating the percentage 
coefficient of variation (% CV) of the results obtained over at least 
two days. 
Accuracy 
Accuracy is reported as % nominal of the analyzed concentration. 
Intra-run Accuracy 
Intra-run accuracy was determined by calculating the percentage 
nominal of the calculated concentration from the actual values for 
quality control samples at each concentration level analyzed in a 
single run and the mean of percentage nominal at each level was 
reported. 
Intra-day Accuracy 
Intra-day accuracy was determined by calculating the percentage 
nominal of the calculated concentration from the actual   values 
for quality control samples at each concentration level analyzed in 
a single day and the mean of percentage nominal at each level 
was reported. 
Inter-day Accuracy 
Inter-day accuracy was determined by calculating the percentage 
nominal of the calculated concentration from the actual value for 
quality control samples at each concentration level analyzed over 
at least two days and the mean of percentage nominal at each 
level was reported. 
Stock Solution Stability 
Short Term Stock Dilution Stability 
The stability of stock dilutions of analyte and the internal standard 
was evaluated at room temperature. Aqueous stock dilution of the 
analyte and the internal standard were prepared.  One portion of 
the stock dilution was placed in the refrigerator between 2-8ĈC, 
while the other portion was placed at room temperature for 24 h. 
Stock dilution stored at room temperature (stability samples) was 
compared with refrigerated stock dilutions considered as 
Âcomparison samplesÊ. Six replicate injections of the above 
solutions were made. 
Long Term Stock Solution Stability 
The stability of the stock solution when stored in the refrigerator 
for a given period of time was determined.  Stock solutions of the 
analyte and internal standard were prepared and stored in the 
refrigerator between 2-8ĈC for 7 days (stability stock).  The stock 
solution stabilities of the analyte and the internal standard were 
determined with a comparison stock solution, which was prepared 
freshly. Five replicate injections of the above solutions were 
made.  The response of comparison samples were corrected by 
multiplying with correction factor to nullify the difference between 
the measured weights or the dilutions made. 
Freeze Thaw Stability  
This test was done to ensure that the analyte was stable in the 
biological matrix even after multiple freeze-thaw cycles. Six quality 
control samples each at low and high concentrations stored below 
ă50ĈC for at least 24 h were removed from the deep freezer and 
were allowed to thaw unassisted at room temperature (fT4 
samples).  These samples were frozen again below ă50ĈC for at 
least 12 h. Another set of six quality control samples at low and 
high concentration levels (fT3 samples) were removed from the 
deep freezer along with the fT4 samples and thawed unassisted.  
Both sets of samples were replaced back into the deep freezer.
 At least after 12 h of freezing, fT4, fT3 and another set of six 
samples each at low and high concentration levels (fT2 samples) 
were removed from the deep freezer and thawed unassisted.  All 
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the samples were replaced back into the deep freezer. At least 
after 12 h of freezing, fT4 samples were taken out from deep 
freezer, thawed unassisted to room temperature and analyzed 
with freshly prepared calibration curve (CC) solutions.    
Bench Top (BT) Stability 
Six quality control samples each at Quality Control sample at Low 
concentration (QCL) and Quality Control sample at High 
concentration (QCH) levels were stored at room temperature for 3 
and 6 h. The above samples were analyzed along with freshly 
prepared calibration curve standards by using the method being 
validated. 
Long-Term (LT) Stability 
To assess the stability of the analyte in the biological matrix under 
the same conditions of storage as that of the study samples for 
the time period between the date of first sample collection and the 
date of last sample analysis, the following test was performed. 
Six samples of each quality control samples at low and high 
concentrations were stored below -50ĈC in the deep freezer. The 
stability of the analyte was evaluated by comparing each of the 
back calculated concentrations of stability Quality Control sample 
(QCs) with the mean concentrations of the respective QCs 
analyzed in the first  accepted  precision  and  accuracy batch. 
Auto sampler Stability 
To evaluate the stability of the samples in the autosampler after 
processing for the anticipated run time, six sets of quality control 
samples each at low and high concentrations were placed in the 
auto sampler for 24 h and 48 h. The quality control samples were 
retained in the autosampler to prove auto sampler stability. After 
the lapse of the test time, the samples placed in the auto sampler 
were injected into the system along with freshly prepared 
calibration curve standards. The stability of the analyte was 
evaluated by comparing the back calculated concentration of 
stability samples from the freshly prepared calibration curve with 
their respective nominal concentrations. 
To determine the auto sampler stability of the internal standard, 
the mean peak area obtained for the internal standard of the 
stability samples was compared with that of the mean of internal 
standard area of accepted non-zero calibration curve solution 
(CCÊs) and the percent change was calculated. 
Recovery 
Absolute recovery of a bio analytical method is the measured 
response obtained from a certain amount of analyte added to and 
extracted from the biological matrix, expressed as a percentage of 
the response obtained for the true concentration of the pure 
authentic standard which has not been subjected to the extraction 
procedure. To determine recovery of this method, six replicates of 
aqueous quality control samples (un extracted) with 
concentrations close to spiked Quality Control sample at Low 
concentration (QCL), Quality Control sample at Middle 
concentration (QCM) and Quality Control sample at High 
concentration (QCH) concentration (extracted) were prepared. 
These un extracted samples were injected along with precision 
and accuracy batch. The mean and standard deviation for the 
percent recovery obtained and there by the percent variation 
(%CV) was calculated at each concentration level. The overall 
percent recovery was calculated as the mean of recoveries 
obtained at the three quality control levels (QCL, QCM and QCH). 
The overall percent variation (% CV) was also calculated. The 
percentage recovery for the internal standard was also calculated. 
The peak area response of the internal standard obtained for the 
extracted QCM sample (analyzed in the precision and accuracy 
batch) was compared with the mean area response of the internal 
standard obtained for the un extracted QCM samples.  
Ruggedness 
Ruggedness of the method was studied by changing the 
experimental conditions such as operators, instruments, source of 
reagents, solvents and column of similar type. Chromatographic 
parameters such as retention time, asymmetric factor, capacity 
factor and selectivity factor were evaluated. 
Robustness 
Robustness of the method was studied by injecting the standard 
solutions with slight variations in the optimized conditions namely, 
μ 1% in the ratio of acetonitrile in the mobile phase, μ 0.5 units in 
the pH of the buffer, μ 0.5 mL volume of the triethylamine in 
aqueous phase and μ 0.1 mL of the flow rate 
Clinical design 
The study protocol was approved by The Institution Ethics 
Committee. Twenty four healthy male Indian subjects with mean 
age group 20ă30 years and average weight 65.8μ6.1 kg were 
included in the study. Subjects were excluded from the study if 
one of more of following criteria were present at time of medical 
screening: allergic to losartan potassium, history or clinical data of 
renal or liver disease, positive test for hepatitis B, HIV, history of 
alcohol, drug addiction or donated blood within 72 days prior to 
study. Test and reference formulation of losartan potassium 25.0 
mg tablet were administered with 240 ml of water. The study was 
conducted according to the principles outlined in the declaration of 
Helsinki. The study was conducted as 12ï2 single dose, 
randomized, open, 
and complete crossover design. Volunteers were fasted overnight 
before and 4 h after  
drug administration. Blood sample (5 ml) were collected at 0.00 h 
and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 18.0 and 24.0 of 
post drug administration through an indwelling cannula into 
heparinised glass vials. After drug administration standard 
breakfast and lunch were provided at 4 and 6 h post dose. The 
blood samples were immediately centrifuged, plasma was 
separated and stored at î20 ◦C until analysed. After a washout 
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period of 7 days, the study was repeated in the same manner to 
complete the crossover design. The plasma samples obtained at 
various time intervals were analysed by the HPLC method 
developed. 
Pharmacokinetic analysis 
The plasma concentration profile obtained was fed into PK 
solution, computer software on Microsoft excel®, to determine the 
pharmacokinetic parameters. The maximum losartan potassium 
concentration Cmax and the corresponding peak time Tmax were 
determined by the inspection of the individual drug plasma 
concentrationătime profiles. The elimination rate constant Kel was 
obtained from the least-square fitted terminal log-linear portion of 
the plasma concentrationătime profile. The elimination half-life 
T1/2 was calculated as 0.693/Kel. The area under the curve to the 
last measurable concentration (AUC0ăt) was calculated by the 
linear trapezoidal rule. The area under the curve extrapolated to 
infinity (AUC0ă¥) was calculated asAUC0ăt +Ct/Kel where Ct is the 
last measurable concentration. 
Result and Discussion 
Development of Losartan potassium SR tablets 
The physical properties of different batches of developed tablets 
are given in Table 2 of losartan potassium respectively. All the 
batches showed uniform thickness. The average percentage 
deviation of 20 tablets of each formula was less than μ 5% and 
hence all formulations passed the test for uniformity of weight as 
per official requirements (Pharmacopoeia of India 1996). Good 
uniformity content was found among three different batches of 
tablets. Another measure of tablets strength is friability. In the 
present study, the percentage friability for all the formulations was 
below 1%, indicating that the friability is within the prescribed 
limits. All the tablets formulations showed acceptable pharmaco 
technical properties and complied with the specifications for 
weight variation, drug content, hardness and friability.  
In vitro release  
A suitable in vitro dissolution method serves as a valuable quality 
control tool to assess batch to batch release performance and to 
assure the physiological availability of the drug. The in vitro 
dissolution test is also used to guide formulation development and 
to monitor manufacturing process. As a regulatory test, it is used 
to approve minor changes in formulation, changes in the site of 
manufacturing and also to assess the scale-up of the bio-batch to 
the production batch. 
All the batches have shown that as the polymer concentration 
increases, the drug release rate decreases for losartan 
potassium. (Figure 1). 
The in vitro drug release characteristics of the developed 
sustained release (SR) and the marketed immediate release (IR) 
tablets were studied. Dissolution data for all the experiments were 
highly reproducible and hence only the average values were 
plotted. The dissolution of the marketed IR tablets indicated that 
more than 80% of the drug is released within 1h, which complies 
with the pharmacopoeial specifications. In all the batches, we 
observed that as the polymer concentration increases, the drug 
release rate decreases.  
To know the mechanism of drug release from these formulations, 
the data were treated according to zero-order (cumulative amount 
of drug released versus time), first-order (log cumulative 
percentage of drug released versus time), Higuchi (Cumulative 
percentage of drug released versus square root of time) and 
Peppas (log cumulative percentage of drug released versus log 
time) equations 19-21 which are clearly revealed in Figure 2-5 for 
losartan potassium. In vivo studies were carried out for the 
optimized formulation (F3) in twelve healthy human volunteers 
and the pharmacokinetic studies were carried out for the 
optimized formulation and compared with the marketed 
formulation. 
Bioavailability study design and data handling 
A single dose, randomized, complete, two treatments cross over 
study was conducted in healthy human subjects for the selected 
drug formulations.  Twelve volunteers aged between 20-30 years 
were selected. Seven days prior to the commencement of the 
study, volunteers were subjected to preliminary screening, 
standard clinical and biochemical investigations. 
After overnight fasting, the volunteers were given code numbers 
and allocated to the treatment in accordance with the randomized 
code. The order of treatment administration was randomized in 
two sequences (AB and BA) in blocks of two.  In each dosing 
session, volunteers received Reference Product A (Immediate 
release formulations) and Test B (Sustained release 
formulations). A wash out period of seven days was allowed 
between dose administrations. Blood samples (4 ml) were 
collected at 0 (before drug administration), 0.5, 1.0, 1.5, 2.0, 2.5, 
3.0, 4.0, 6.0, 8.0, 12.0, 18.0 and 24.0 h post dosing. The samples 
were centrifuged and plasma was separated. There were no 
serious adverse effects observed during the entire study.   
Validation of HPLC methods  
Estimation of the drugs selected 22 in plasma samples from the 
volunteers was carried out using optimized chromatographic 
conditions. The validation parameters such as accuracy, precision 
(repeatability and reproducibility), linearity and range, sensitivity 
(limit of detection and limit of quantitation), 
robustness/ruggedness, stability, selectivity/specificity and system 
suitability were evaluated.  
Specificity 
HPLC-UV analysis of the blank human plasma samples showed 
the separation of losartan potassium and nifidipine no interference 
with either of these was observed. Hence the specificity of the 
method was established by comparison with human plasma 
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(control). Representative chromatograms of extracted blank 
plasma, are shown in Fig. 6. Indicating no interference in the 
blank plasma and in drug-free human plasma at the retention time 
of 5.2 for the drug losartan potassium and at the retention time of 
10.6 for the IS.  
Sensitivity  
The limit of reliable quantitation was set at the concentration of 
the LOQ QC, 20.0 ng/mL for losartan potassium and lowest non-
zero standard (Fig. 7).  
Linearity  
A regression equation with a weighing factor of 1/concentration2 
was judged to produce the best fit for the concentration/detector 
response relationship for losartan potassium in human plasma. 
The linearity range for losartan potassium was found to be 20.0, 
60.0, 80.0, 101.0, 120.0, 150.0, 182.0 and 300.0 ng/ml. The curve 
is given in Figure 8 with correlation coefficient (r2) was greater 
than 0.99.  
Precision and Accuracy 
The precision of the assay was measured by the percent 
coefficient of variation over the concentration range of LOQ, low, 
middle and high quality control sample of losartan potassium 
during the course of validation. The accuracy of the assay was 
defined as the absolute value of the ratio of the calculated mean 
values of the LOQ, low 100.097μ1.297, 99.10%, middle 
149.514μ0.378, 99.67 and high 181.716μ0.518, 99.84 quality 
control samples to their respective nominal values, expressed as 
percent.  
Stabilities 
The stability studies of plasma samples spiked with selected 
drugs were subjected to three freeze-thaw cycles, short term 
stability at room temperature for 3 h and  long term stability ată
70oC over four weeks. In addition, stability of standard solutions 
was performed at room temperature for 6 h and freeze condition 
for four weeks. The mean concentrations of the stability samples 
were compared to the theoretical concentrations. The results 
indicate that selected drugs in plasma samples can be stored for 
a month without degradation in frozen state. The results of short 
term storage at room temperature 
stability100.78μ0.625,0.620,99.78 and 
180.316μ1.341,0.744,99.07 and freeze-thaw cycles indicate no 
degradation of selected drugs in plasma as well as in sample 
solution and hence plasma samples could be handled without 
special precautions.  
Recovery  
Analyte recovery from a sample matrix (extraction efficiency) is a 
comparison of the analytical response from an amount of analyte 
added to that determined from the sample matrix. 86.29,87.95 
and 84.28 results indicate that the recovery of losartan potassium 
was consistent at all levels. 
Ruggedness and robustness 
The ruggedness and robustness of the methods were studied by 
changing the experimental conditions.  No significant changes in 
the chromatographic parameters were observed when changing 
the experimental conditions (operators, instruments, source of 
reagents and column of similar type) and optimized conditions 
(pH, mobile phase ratio and flow rate). 
In vivo data analysis 
Pharmacokinetic parameters such as peak plasma concentration 
(Cmax), time to peak concentration (tmax), area under the plasma 
concentration-time curve (AUC0-t & AUC0-¥), elimination rate 
constant (kel) and elimination half-life (t1/2) were calculated 
separately and the blood level data of selected formulations were 
compared and are presented in the Table 3. Mean plasma 
concentration-time profile of losartan potassium was given in 
Figure 3. 
Statistical analysis  
The pharmacokinetic parameters of two different drug 
formulations of losartan potassium were compared statistically by 
one way ANOVA (analysis of variance) using SPSS version 16.0. 
P-value of <0.05 was considered as statistically significant. The 
results were expressed as the mean μ S.D. The pharmacokinetic 
parameters Cmax, AUC0-t and AUC0-∞ of the immediate release 
and sustained release formulations of losartan potassium were 
found to be significantly different by one way ANOVA. 
Conclusion 
The sustained release tablets of losartan potassium were well 
absorbed and the extent of absorption was higher than that of the 
marketed tablet. An HPLCăUV based method has been 
developed for quantification of losartan potassium in human 
plasma. The sensitivity and simplicity of the method makes it 
suitable for pharmacokinetic studies. The statistical comparison of 
AUC and Cmax clearly indicated no significant difference in the 
two formulations of 25.0 mg of losartan potassium tablets.  
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Figure 1: Release profiles of Losartan potassium from HPMC (polymer) containing Formulation 
 
 
Figure 2: Zero order chart of optimized Losartan potassium formulation 
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Figure 3: First order chart of optimized Losartan potassium formulation 
 
  
Figure 4: Higuchi chart of optimized Losartan potassium formulation 
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Figure 5: Peppas chart of optimized Losartan potassium formulation 
  
Figure 6: Typical chromatogram of Blank Plasma 
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Figure 7: Typical chromatogram of Standard 
  
Figure 8: Calibration curve of Losartan potassium 
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Figure 9: Mean plasma concentration-time profile of Losartan potassium       from developed Sustained release tablets (test) and marketed 
immediate release tablet (Reference) 
Table 1 : Formulation prepared by wet granulation method (F1-F16) for Losartan potassium  
 
 
Fa  LP  HPMC Xanthen Avicel Magnesium  Aerosil PVP-K-20/30  Total 
        Ph 101 Stearate         (mg/tab) 
 
 
F1  25  5  -----  62   2   1   5   100   
F2  25  10  -----  57   2   1   5   100   
F3  25  15  -----  52   2   1   5   100   
F4  25  20  -----  47   2   1   5   100   
F5  25  25  -----  42   2   1   5   100   
F6  25  30  -----  37   2   1   5   100   
F7  25  35  -----  32   2   1   5   100   
F8  25  40  -----  27   2   1   5   100   
F9  25  -----  5  62   2   1   5   100   
F10  25  -----  10  57   2   1   5   100   
F11  25  -----  15  52   2   1   5   100 
F12  25  -----  20  47   2   1   5   100 
F13  25  -----  25  42   2   1   5   100 
F14  25  -----  30  37   2   1   5   100  
F15  25  -----  35  32   2   1   5   100  
F16  25  -----  40  27   2   1   5   100 
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a Code of formulations  
 
Table 2 : Comparison of the physical properties of the matrix tablets containing losartan potassium  
 
 
Formulation Hardness (Kg/cm2)b Thickness (mm)b  Weight (g)b   Friability (%)b  
Fa 
F1   5.1μ0.65    3.6320μ0.04   0.1056μ0.0011  0.357μ0.07 
F2   5.0μ0.79    3.6080μ0.05   0.1058μ0.0016  0.357μ0.07 
F3   5.0μ0.61    3.6020μ0.05   0.1058μ0.0013  0.387μ0.08 
F4   4.9μ0.82    3.6240μ0.03   0.1062μ0.0015  0.352μ0.06 
F5   5.0μ0.79    3.5920μ0.03   0.1064μ0.0011  0.351μ0.08 
F6   5.1μ0.65    3.6060μ0.05   0.1048μ0.0008  0.328μ0.06 
F7   5.0μ0.79    3.6100μ0.02   0.1060μ0.0010  0.349μ0.05 
F8   4.6μ0.65    3.6080μ0.04   0.1056μ0.0009  0.328μ0.11 
F9   5.0μ0.79    3.6080μ0.04   0.1058μ0.0008  0.298μ0.05 
F10   5.3μ0.83    3.6160μ0.02   0.1066μ0.0011  0.347μ0.05 
F11   5.0μ0.79    3.5880μ0.05   0.1058μ0.0008  0.348μ0.05   
F12   5.1μ0.74    3.5960μ0.03   0.1066μ0.0011  0.349μ0.12   
F13   4.7μ0.57    3.5028μ0.03   0.1062μ0.0008  0.361μ0.07 
F14   5.2μ0.57    3.5720μ0.03   0.1058μ0.0008  0.342μ0.06 
F15   5.0μ0.79    3.600μ0.01    0.1060μ0.0012  0.384μ0.05 
F16   5.1μ0.82    3.6100μ0.02   0.1062μ0.0015  0.363μ0.07 
 
a Code of formulations,b Results represents the mean of replicate determination with the standard deviation given in parenthesis 
 
Table 3 : Mean pharmacokinetic profile (n=6) 
    Cmax  Tmax    AUC0-t   T1/2   Keli   AUC0-t∞ 
I R   201.177 μ1.503   2.333 μ0.258 856 362 μ91.640   2.882 μ0.096  0.237 μ0.014  945.306 μ87.774 
S R    200.302μ2.523†     5.333μ1.032†      2146.630μ248.330†     6.080μ0.125† 0.114μ0.002† 2337.663μ252.467† 
   
† Significantly higher than Immediate Release tablets. 
Ú Significantly lower than Immediate Release tablets. 
SR Sustained release   
 
 
 
 
